Table 2 Major spike mutations
From: Emerging SARS-CoV-2 variants of concern and potential intervention approaches
Mutating residues | Mutation | Region | Pathophysiology | Clinical Impact expectations | Major variants | |||||
|---|---|---|---|---|---|---|---|---|---|---|
ACE2 affinity | Immune escape# | Transmissibility | Virulence | Alpha B.1.1.7 | Beta B.1.351 | Gamma P.1 | Delta &Kappa B.1.617.2/1 | |||
K417 | K417N | RBD | ↑ | ↑ | ↑ | ↑ |  | √ |  |  |
K417T | ↑ | ↑ | ↑ | ↑? |  |  | √ |  | ||
L452 | L452R | ↑ | ↑ | ↑ | ↑ |  |  |  | √ | |
T478 | T478K | ↑ | ↑ | ↑ | ↑? |  |  |  | √ (Delta) | |
E484 | E484K | ↑ | ↑ | ↑? | ↑? | √ (partially) | √ | √ |  | |
E484Q | ↑ | ↑ | ↑? | ↑? |  |  |  | √ | ||
N501 | N501Y | ↑ | ↑ | ↑ | ↑ | √ | √ | √ |  | |
D614 | D614G | non-RBD | ↑ | ↑ | ↑ |  ↔  | √ | √ | √ | √ |
P681 | P681H | S1/S2 Furin cleavage site |  ↔  | ↑? | ↑ | ↑? | √ |  |  |  |
P681R |  ↔  | ↑? | ↑ | ↑? |  |  |  | √ | ||